New Advances in Treating Aggressive Thyroid Cancers: Fudan Cancer Hospital Presents an Exploratory “China Strategy” at a Leading International Oncology Congress
Most types of thyroid cancer progress slowly and respond well to treatment. However, two subtypes are particularly aggressive: anaplastic thyroid carcinoma (ATC) and poorly differentiated thyroid carcinoma (PDTC). ATC is one of the most rapidly progressing thyroid malignancies, with a historical median overall survival (OS) of only approximately five months and a 1-year OS rate of around 20%. Although PDTC generally has a better prognosis than ATC, it is highly heterogeneous. Historically, the overall 5-year OS rate has been approximately 60%–70%; however, once the disease becomes locally advanced, unresectable, or metastatic, patient outcomes deteriorate significantly. For a long time, effective treatment options for these patients have been extremely limited.



